Bioprocess Scale-Up Patents: Who Leads, Where the Gaps Are 2026
- One filer, the whole field. The assignee ranking returns a single company, Pow Genetic Solutions, holding 100.0% of all 15 records in scope — there is no second filer to compare against.
- Culture-condition optimization is the cited anchor. WO2023122224A2 and its US counterpart US20240209306A1, both on iterative culture-condition optimization, carry the highest citation counts in the set at 8 and 4 respectively.
- Bioreactor hardware claims are thin. C12M (bioreactors & enzyme apparatus) appears in only 26.7% of the 15 records, well behind the 86.7% carrying C12N microorganism and genetic-engineering claims.
What the bioprocess scale-up filings actually cover
The search string pairs upstream scale-up and fermentation-scaling language with the operational vocabulary that makes a filing relevant in practice: culture conditions, gene constructs, metabolite production, host strain and gene expression. The 15 records this returns are not a broad slice of biomanufacturing patenting generally — they are the narrow intersection where scale-up methodology and molecular biology claims overlap in the same document. That intersection is dominated by iterative culture-condition optimization: methods that perturb a bioreactor’s operating parameters in continuous culture and use the output to select the next set of parameters.
Filing activity in this dataset peaked in 2022 at 11 records, and the most recent complete years show the usual publication lag — a filing made today will not show up in the record for roughly 18 months, so the last year or two in any trend chart understates real activity.
Let an AI agent run this analysis on your own technology
Pick a task. Every answer cites the patents behind it.
Filing trend and technology composition
The dataset is small enough that every figure below should be read as a description of this specific 15-record set, not as a proxy for the wider bioprocess field.
A single peak year, then a partial tail
Filings in scope run from 2017 through the 2026 cut-off, with 2022 the peak year at 11 records. With fewer than four complete years once the ~18-month publication lag is accounted for, a growth rate cannot be stated responsibly from this trend alone.
Molecular biology and computation dominate the IPC mix
C12N (microorganisms & genetic engineering) appears on 86.7% of the 15 records, closely followed by G16B bioinformatics at 73.3% and G06N AI-based computing at 66.7%. Hardware-facing classes — C12M bioreactors at 26.7%, G01N material analysis and G05B control systems each at 6.7% — are comparatively rare, which tells you the claim activity here sits mostly in the biological and computational layers rather than in reactor hardware.
Shares are the percentage of the 15 records in scope. A patent can carry several IPC classes, so the shares add up to more than 100%.
Go deeper on Bioprocess Scale-Up Patent Landscape with Eureka
This page is one run against one query. Ask Eureka your own question about bioprocess scale-up patent landscape and every answer comes back with the patent numbers behind it.
Try EurekaThe most-cited filings in this set
Methods and Systems for Optimizing Culture Conditions in a Culture Process
Methods and systems for iteratively improving culture conditions for at least one culture output in a continuous bioreactor process: maintaining a continuous culture under a set of culture parameters, measuring a culture output, then iteratively selecting and testing new parameter sets predicted to improve that output while the cells remain in continuous culture.Filed by Pow Genetic Solutions; published 2024-06-27. Its PCT counterpart WO2023122224A2 is the single most-cited record in this dataset.
| # | Publication no. | Patent title | Citations |
|---|---|---|---|
| 1 | WO2023122224A2 | Methods and systems for optimizing culture conditions in a culture process | 8 |
| 2 | US20240209306A1 | Methods and Systems for Optimizing Culture Conditions in a Culture Process | 4 |
Citation counts inside a single searched corpus are a signal of influence within that corpus, not a ranking of current commercial importance — older filings accumulate citations simply by being available longer.
Publication numbers are shown where the record carries one (2 of 2 rows); clicking a row searches Eureka by that number.
Put your own technology through the same analysis
Eureka on the web
When you want the answer in the next five minutes.
The agent works the prompt against patents and technical literature, citing every source.
Run your analysis now →MCP server & REST API
When it has to run inside your own pipeline.
Patent search, landscape analysis and assignee resolution as MCP tools. Drop them into any agent framework, or call REST directly.
Browse MCP servers →What the composition and concentration mean for a filing decision
Three things stand out once the IPC mix and the assignee concentration are read together: the claim space is biological and computational rather than mechanical, one filer currently owns the whole record set, and the highest-cited pair of documents defines the anchor claim most new entrants will need to work around.
No comparison point exists in this dataset
The assignee ranking returns one company across all 15 records in scope. That is not a market share statement about bioprocess scale-up broadly — it reflects how narrowly this search string is drawn — but within these 15 records there is no second filer to benchmark against.
Biology and data claims outnumber hardware claims
C12N microorganism and genetic-engineering claims sit on 86.7% of the 15 records, while C12M bioreactor and enzyme-apparatus claims sit on only 26.7%. Read together with G16B (73.3%) and G06N (66.7%), the claim activity in this set is concentrated on strain, gene construct and computational-optimization language rather than on reactor vessel design.
One method pair sets the reference point
WO2023122224A2 and its US counterpart US20240209306A1 are the two most-cited records in the set, both directed to iterative culture-condition optimization in continuous culture. Any new filing on adaptive or model-driven culture control should expect examiners and competitors to cite this pair first.
Eureka can read the same corpus for gaps instead of for coverage: under-claimed branches adjacent to bioprocess scale-up patent landscape, with the prior art for and against each one.
Who is filing, and what is still unclaimed
With a single assignee returned across all 15 records, this section reads less like a competitive map and more like a description of one filer's claim footprint — and of the sub-areas that footprint does not yet cover.
Pow Genetic Solutions
The only assignee returned by the ranking, holding every one of the 15 records in scope, including the two most-cited filings on iterative culture-condition optimization in continuous bioreactor culture.
PCT is the preferred filing route
Four of the 15 records entered via the WIPO/PCT route, ahead of Europe (2) and single filings each in AE, Australia, Canada and India. That pattern points to an applicant seeking broad optionality before committing to national phase, rather than one filing jurisdiction-by-jurisdiction from the start.
2022 is the filing high point so far
Filing activity across 2017–2026 peaks in 2022 at 11 records. Because publication lags filing by roughly 18 months, the most recent one to two years in this trend will understate actual filing activity rather than reflect a genuine drop-off.
| Assignee | Recent year | YoY |
|---|---|---|
| Pow Genetic Solutions, Inc. | 0 | — |
Where to take this analysis
The record count here is small enough that any conclusion should be checked against the underlying filings rather than taken from the aggregate figures alone.
Read the two anchor filings in full
WO2023122224A2 and US20240209306A1 define the highest-cited claim language on iterative culture-condition optimization in this set. Understanding their exact claim scope is the first step before drafting anything adjacent.
Open the featured filingCheck the under-claimed branches against live filings
The gateChips above point to sub-areas with thin IPC density in this dataset, not confirmed white space — a fuller freedom-to-operate check needs the underlying documents, not just the subclass counts.
Explore in Patsnap EurekaCommon questions about bioprocess scale-up patents
Within this 15-record dataset, the assignee ranking returns a single company, Pow Genetic Solutions, holding all 15 records, or 100.0% of the set. That does not mean the company owns 100% of bioprocess scale-up patenting worldwide — it reflects how narrowly this particular search string is drawn around culture-condition, gene construct and metabolite-production claims layered on scale-up language. A broader search string covering fermentation scale-up generally would likely surface additional filers.
US20240209306A1 claims methods and systems for iteratively improving culture conditions for a culture output in a continuous bioreactor process: maintaining cells under an initial set of culture parameters, measuring the output, then selecting and testing a new parameter set predicted to improve that output while keeping the culture continuous. It is the US counterpart to WO2023122224A2, the most-cited record in this dataset at 8 citations. Anyone building an automated or model-driven culture-optimization loop should read its claims closely, since it is the anchor reference point in this claim space.
Not heavily, based on this dataset. C12M, the IPC subclass for bioreactors and enzyme apparatus, appears on only 26.7% of the 15 records, compared with 86.7% for C12N microorganism and genetic-engineering claims. The claim activity here sits mostly in strain engineering, gene expression and computational optimization (G16B, G06N) rather than in reactor vessel or hardware design, which suggests hardware-specific claims are comparatively less crowded in this particular slice.
A growth rate cannot be responsibly stated from this dataset. Filing activity peaked in 2022 at 11 records within the 2017–2026 window, but fewer than four complete years remain once the roughly 18-month publication lag is factored in, so the most recent years understate true filing activity rather than showing a real decline. Treat the 2022 peak as the clearest data point available and wait for later years to mature before drawing a trend conclusion.
Based on the IPC composition of this dataset, sub-areas tied to bioreactor sensor and control integration, real-time material-analysis feedback (G01N), and scale-down model validation carry noticeably thinner claim density than the core culture-optimization and genetic-engineering classes. These are not confirmed gaps — they reflect low counts in a 15-record set — but they are reasonable starting points for a freedom-to-operate check before assuming the field is fully occupied.
Research Bioprocess Scale-Up Patent Landscape in depth with Eureka
Go past this page: query the whole bioprocess scale-up patent landscape corpus yourself, in your own scope.
Every answer comes back with patent numbers you can open.
Disclaimer. This page is generated from Patsnap Eureka data drawn from a limited snapshot of global patent and scientific-literature records, and is provided for general information and reference only.
Patent data carries inherent limitations: recent filings (typically the most recent 18–24 months) are under-counted due to standard publication lag; counts may be reported at either a patent-family or a patent-record basis and are not always directly comparable; classification, applicant-name, and citation data may contain errors, duplicates, or omissions; and the underlying search query defines and constrains the scope shown. As a result, the analysis may be incomplete or inaccurate and may not reflect the full technology landscape.
Nothing on this page constitutes an exhaustive prior-art, novelty, freedom-to-operate, or validity search, nor does it constitute legal, financial, investment, or professional advice, and it should not be relied upon as such. Any patent, commercial, or strategic decision should be verified independently and reviewed with qualified patent, legal, and domain professionals. Patsnap makes no warranties, express or implied, as to the accuracy, completeness, or fitness for any particular purpose of the information presented.
Machine translation. Assignee and organisation names originally recorded in Chinese, Japanese or Korean have been rendered into English by an AI translation step so that the tables stay readable. These renderings are best-effort and may not match a company’s registered English name; the original name is what the underlying patent record carries, and it is what any Eureka query launched from this page uses.